drugset / Trial / NCT06893016
Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this study is to demonstrate that RAY1225 is superior to placebo for percent change in body weight.
Timeline
- Start
- 2025-06-15
- Primary completion
- 2026-06-15
- Completion
- 2026-09-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RAY1225 | Unknown | — | Subcutaneous |